

# Accepted Manuscript

Considerations for Successful Treatment-Free Remission in Chronic Myeloid Leukemia

Stuart L. Goldberg, MD, Michael Savona, MD, Michael J. Mauro, MD



PII: S2152-2650(17)30991-6

DOI: [10.1016/j.clml.2017.11.006](https://doi.org/10.1016/j.clml.2017.11.006)

Reference: CLML 1035

To appear in: *Clinical Lymphoma, Myeloma and Leukemia*

Received Date: 21 July 2017

Revised Date: 4 October 2017

Accepted Date: 22 November 2017

Please cite this article as: Goldberg SL, Savona M, Mauro MJ, Considerations for Successful Treatment-Free Remission in Chronic Myeloid Leukemia, *Clinical Lymphoma, Myeloma and Leukemia* (2017), doi: 10.1016/j.clml.2017.11.006.

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

**REVIEW****Considerations for Successful Treatment-Free Remission in Chronic Myeloid Leukemia**

Stuart L. Goldberg, MD<sup>a</sup>; Michael Savona, MD<sup>b</sup>; and Michael J. Mauro, MD<sup>c</sup>

<sup>a</sup>John Theurer Cancer Center, 7650 River Road, Suite 200, North Bergen, NJ, 07047, email: stuart.goldberg@hackensackmeridian.org; <sup>b</sup>Vanderbilt-Ingram Cancer Center, Vanderbilt University

Medical Center, 2220 Pierce Ave, 777 PRB, Nashville, TN 37232-6307, email:

michael.savona@vanderbilt.edu; <sup>c</sup>Memorial Sloan Kettering Cancer Center, 1275 York Avenue, Box 489, New York, NY 10065, email: maurom@mskcc.org

**Corresponding author:**

Stuart L. Goldberg, MD

John Theurer Cancer Center

7650 River Road, Suite 200

North Bergen, NJ 07047

Phone: 201-464-0008

Fax: 201-662-1267

Email: stuart.goldberg@hackensackmeridian.org

**Running title:** Treatment-Free Remission in CML

**Keywords:** minimal residual disease, deep molecular response, nilotinib, imatinib, dasatinib

**Abstract word count:** 103 (limit, 250)

**Text word count:** 3249 (limit, 10000)

**References:** 69 (range, 50-120)

**Tables/Figures:** 2 tables/0 figures (limit, 7 combined)

Download English Version:

<https://daneshyari.com/en/article/8615614>

Download Persian Version:

<https://daneshyari.com/article/8615614>

[Daneshyari.com](https://daneshyari.com)